Phase 2 Melanoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who are well enough to carry out daily activities with little to no limitation (based on a standard medical scale called ECOG, scoring 0 to 2)
• People who have been diagnosed with either non-small cell lung cancer (NSCLC) or skin melanoma that has spread to other parts of the body, confirmed by a tissue sample
• People with NSCLC whose cancer does not have certain specific gene changes (EGFR mutations, or ALK, ROS1, or RET gene rearrangements)
• People with NSCLC who have already been treated with a combination of immune therapy (anti-PD-(L)1) and platinum-based chemotherapy, either as their first treatment or across their first and second treatments for advanced disease
• People with NSCLC who received immune therapy (anti-PD-(L)1) for more than 6 months and whose cancer then started growing again
• People with skin melanoma who have already received immune therapy (anti-PD-1), either alone or combined with another type of immune therapy (anti-CTLA4), for advanced disease
• People with skin melanoma who carry a specific gene change (BRAF V600 mutation) and have also been treated with targeted therapies (BRAF and MEK inhibitors)
• People with skin melanoma who received immune therapy (anti-PD-1, with or without anti-CTLA4) for more than 6 months and whose cancer then started growing again
• People willing and able to provide written consent to participate

Who may not be able to join:

• People with significant heart problems, including severe or unstable coronary artery disease, a history of heart attack, serious heart failure (classified as New York Heart Association Class III or IV), or dangerous irregular heart rhythms
• People who have had a stroke or a mini-stroke (transient ischemic attack) within the 6 months before screening
• People with high blood pressure that is not well controlled
• People with a history of another cancer, unless it was a minor skin cancer, or an early-stage cervical or breast cancer that went into full remission at least 2 years before joining the trial and requires no further treatment during the study (confirm with trial site regarding cancers affecting the liver)
• People with cancer that has spread to the brain or spinal cord, unless those areas have already been adequately treated
• People whose blood test results show low levels of certain blood cells or abnormal blood counts (low white blood cells, low platelets, or low haemoglobin)
• People with certain abnormal liver function blood test results, unless a specific inherited condition called Gilbert syndrome applies (confirm with trial site)
• People with certain other abnormal liver enzyme levels in blood tests
• People with reduced kidney function shown by blood test results
• People with a history of blood clots in veins or arteries
• People with known allergies to any components of the study drugs
• People currently taking certain medications known to affect the heart's electrical activity in a way that could cause a dangerous heart rhythm
• People currently receiving any other cancer treatment, including radiation therapy
• Women who are pregnant or breastfeeding
• People who still have unresolved side effects rated moderate or worse from previous cancer treatment (with some exceptions such as hair loss or mild nerve-related symptoms)
• People with any other serious uncontrolled medical condition, active infection, or mental health condition that, in the investigator's opinion, could affect their ability to participate safely or reliably in the trial

Important: Always verify eligibility with the trial site directly before applying.